[SCHEDULE 13G] DallasNews Corporation Series A SEC Filing

Rhea-AI Filing Summary

Telomir Pharmaceuticals (NASDAQ: TELO) filed an 8-K disclosing that on 18 July 2025 it sold 1,100,000 common shares through its at-the-market facility at an average price of $2.6045, a premium to the prior day’s close. The block trades were placed with institutional investors and executed by Rodman & Renshaw on the StockBlock platform. Gross proceeds totalled ≈$2.9 million before fees; no warrants or other equity sweeteners were issued.

The transaction immediately increases cash while modestly diluting existing shareholders via the new share issuance. Because the raise was completed at a premium and without warrant overhang, the near-term balance-sheet impact is positive, though future EPS will be spread over a larger share count.

Positive

• $2.9 million gross proceeds improve short-term liquidity.
• Shares were sold at a premium to prior close, indicating investor demand.
• Financing involved no warrants, avoiding future overhang.

Negative

• Issuance of 1.1 million new shares dilutes existing shareholders.

Insights

Financial Analyst

TL;DR: Small ATM raise nets $2.9 m at premium; cash up, dilution modest, overall neutral-positive for liquidity.

The company tapped its at-the-market program for 1.1 m shares, obtaining a premium price without warrants—a sign of institutional appetite and reduced financing risk. While the cash infusion is relatively minor, biopharma firms often need steady capital; this raise buys time without onerous terms. Share count rises, so per-share metrics will edge down, but the absence of discounts or warrant coverage limits pressure on the stock. Given the size, I view the event as liquidity-enhancing yet not transformational.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

DallasNews Corp

(Name of Issuer)

Series A Common Stock

(Title of Class of Securities)

235050101

(CUSIP Number)

07/15/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 235050101

1

Names of Reporting Persons

Beryl Capital Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 470,309.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 470,309.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

470,309.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

IA, OO

Comment for Type of Reporting Person: Percentage calculated based on 4,739,014 shares of Series A Common Stock outstanding on April 28, 2025, as disclosed in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2025.

SCHEDULE 13G

CUSIP No. 235050101

1

Names of Reporting Persons

Beryl Capital Management LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 470,309.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 470,309.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

470,309.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

IA, PN

Comment for Type of Reporting Person: Percentage calculated based on 4,739,014 shares of Series A Common Stock outstanding on April 28, 2025, as disclosed in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2025.

SCHEDULE 13G

CUSIP No. 235050101

1

Names of Reporting Persons

Beryl Capital Partners II LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 355,634.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 355,634.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

355,634.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.5 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Percentage calculated based on 4,739,014 shares of Series A Common Stock outstanding on April 28, 2025, as disclosed in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2025.

SCHEDULE 13G

CUSIP No. 235050101

1

Names of Reporting Persons

David A. Witkin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 470,309.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 470,309.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

470,309.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

HC, IN

Comment for Type of Reporting Person: Percentage calculated based on 4,739,014 shares of Series A Common Stock outstanding on April 28, 2025, as disclosed in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: DallasNews Corp
(b)	Address of issuer's principal executive offices: P. O. Box 224866, Dallas, Texas 75222-4866
Item 2.
(a)	Name of person filing: Beryl Capital Management LLC, a Delaware limited liability company ("Beryl") Beryl Capital Management LP, a Delaware limited partnership ("Beryl GP") Beryl Capital Partners II LP, a Delaware limited partnership (the "Partnership") David A. Witkin Each reporting person disclaims beneficial ownership of Series A Common Stock except to the extent of that person's pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Series A Common Stock covered by this Schedule 13G.
(b)	Address or principal business office or, if none, residence: 225 Avenue I, Suite 205 Redondo Beach, CA 90277
(c)	Citizenship: See Item 4 of the cover sheet for each reporting person.
(d)	Title of class of securities: Series A Common Stock
(e)	CUSIP No.: 235050101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Beryl: 470,309 Beryl GP: 470,309 Partnership: 355,634 David A Witkin: 470,309
(b)	Percent of class: Beryl: 9.9% Beryl GP: 9.9% Partnership: 7.5% David A. Witkin: 9.9%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Beryl: 0 Beryl GP: 0 Partnership: 0 David A. Witkin: 0
	(ii) Shared power to vote or to direct the vote: Beryl: 470,309 Beryl GP: 470,309 Partnership: 355,634 David A Witkin: 470,309
	(iii) Sole power to dispose or to direct the disposition of: Beryl: 0 Beryl GP: 0 Partnership: 0 David A. Witkin: 0
	(iv) Shared power to dispose or to direct the disposition of: Beryl: 470,309 Beryl GP: 470,309 Partnership: 355,634 David A Witkin: 470,309
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. Beryl is the investment adviser to the Partnership and other accounts. Beryl is the general partner of Beryl GP, which is the general partner of the Partnership and other private investment funds. Mr. Witkin is the control person of Beryl.
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Beryl Capital Management LLC

Signature:	/s/ Andrew Nelson
Name/Title:	Chief Operating Officer
Date:	07/18/2025

Beryl Capital Management LP

Signature:	/s/ Andrew Nelson
Name/Title:	Chief Operating Officer of Beryl Capital Management LLC, General Partner of Beryl Capital Management LP
Date:	07/18/2025

Beryl Capital Partners II LP

Signature:	/s/ Andrew Nelson
Name/Title:	COO of Beryl Capital Management LLC, General Partner of Beryl Capital Management LP, General Partner of Beryl Capital Partners II LP
Date:	07/18/2025

David A. Witkin

Signature:	/s/ David A. Witkin
Name/Title:	Reporting person
Date:	07/18/2025

FAQ

How many shares did Telomir Pharmaceuticals sell in the July 2025 offering?

The company sold 1,100,000 common shares through its at-the-market facility.

What price did TELO obtain for the new shares?

Shares were placed at an average price of $2.6045, a premium to the previous trading day’s close.

How much capital did Telomir Pharmaceuticals raise?

Gross proceeds were approximately $2.9 million before fees and expenses.

Were any warrants issued with this financing?

No, the offering did not include warrants; only common shares were sold.

Who facilitated the block trades for TELO’s offering?

Trades were executed by Rodman & Renshaw via the StockBlock platform.